Sirona Biochem Signs International Partnership Agreement with Wanbang Biopharmaceuticals
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate on licencing Sirona’s SGLT2 inhibitor, TFC-039, as a pharmaceutical treatment in both animal and human health. The agreement adds human health to the partnership as a result of new licencing opportunities currently in due diligence.
Wanbang (a wholly owned subsidiary of Shanghai Fosun Pharmaceutical) and Sirona initially signed a licensing agreement for TFC-039, whereby Wanbang obtained the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights. Sirona has since been in discussions with animal health companies to advance TFC-039 as a treatment for diabetes and chronic kidney disease in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections. More recently, Sirona has entered into due diligence with a large pharmaceutical company with a regional interest in developing the compound for human diabetes.
Together, Sirona and Wanbang share extensive knowledge and scientific results of TFC-039. Partnering will significantly increase the speed to third-party partnerships and commercialization. The shared data spans over 12 years of research and development, and includes in vitro and in vivo preclinical work, multiple clinical studies, advanced manufacturing process development and the ability to commercially manufacture TFC-039.
“We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039. Wanbang has invested millions of dollars into the clinical stage research and development of the manufacturing processes for TFC-039. These pieces of data are critical to large organizations and will greatly increase the opportunities to move forward. The probability of a successful licensing agreement has been made much stronger by leveraging our alliance with Wanbang.” said Dr. Howard Verrico, CEO. “We have had a successful year building Sirona’s pipeline, with positive movement on all projects and we’re looking forward to continuing this success with our SGLT2 inhibitor as well as our antiviral and anti-aging projects in 2023.”
About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops, manufactures, and markets drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China. Founded in 1981, the company is headquartered in Xuzhou, China, and is a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and is regarded as one of the top five domestic pharmaceutical companies in China. For more information on Fosun and Wanbang, please visit www.fosunpharma.com/en.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem
Sirona Biochem Signs Research Collaboration Agreement with International Centre for Genetic Engineering and Biotechnology
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a research collaboration with the International Centre for Genetic Engineering and Biotechnology (“ICGEB”) to advance Sirona’s antiviral library of compounds.
ICGEB will immediately begin screening the library of compounds produced at Sirona’s subsidiary TFChem. The work will be performed at the ICGEB’s Laboratory of Molecular Virology located in Trieste, Italy under the direction of Dr Alessandro Marcello, an expert in human virology. Scientists at ICGEB will test the potential antivirals against SARS-CoV-2 (COVID-19) using specialized assays developed at the centre. Previous assays on Sirona’s compounds (performed at another institution) delivered inconclusive results that prevented the company from assessing the value of the suite of compounds. To address this problem, TFChem initiated a collaboration with Dr Marcello’s team at the ICGEB. The testing in his laboratory is ideally suited for this class of antiviral agents and will provide data required to assess the potential of this program.
If the results are promising, it is the intention of the parties to expand the collaboration to further advance these compounds. Ultimately the collective goal is to create new treatment options for SARS-CoV-2 and other viruses. Sirona’s scientists at TFChem require the added expertise in virology to advance this project and this collaboration is a critical step for this program. An enormous unmet need remains in finding better therapies to treat SARS-CoV-2 and numerous other related viruses.
This initial evaluation is estimated to be completed in approximately 12 weeks. An update will be provided after the tests have been performed and the results have been evaluated.
About the International Centre for Genetic Engineering and Biotechnology
Established in 1983 as a special project of UNIDO, the International Centre for Genetic Engineering and Biotechnology – ICGEB is an independent intergovernmental organization with HQ in Trieste (Italy) and with additional laboratories in New Delhi (India) and Cape Town (South Africa). It counts almost 70 Member States. The ICGEB is a not for profit IGO – any revenues generated are re-invested in research and in the funding programs for capacity building in its Member States. The Vision of the ICGEB is to be the world’s leading intergovernmental Organization for research, training and technology transfer in the field of Life Sciences and Biotechnology. Its Mission is to combine scientific research with capacity enhancement, thereby promoting sustainable global development (www.icgeb.org).
The Molecular Virology Group in Trieste studies the detection and molecular mechanisms of different arboviruses and has been mainly involved in the response to the COVID-19 pandemic providing support to the ICGEB Member countries. Activities included in the formulation for protocols for SARS-CoV-2 molecular and serological diagnostics, online tutorials and reagents to be able to develop low-cost in-house assays. COVID-19 viruses circulating in several countries have been sequenced for the first time and made available to the scientific community. A pipeline for testing antivirals against SARS-CoV-2 has been set-up allowing the identification of novel drug candidates.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-1067 and related family of compounds.
“We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica(TM), a leader in the science of skin rejuvenation,” said Dr. Howard Verrico, CEO of Sirona Biochem. “Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing. We would like to thank Dr. Linda Pullan of Pullan Consulting who assisted with our current success.”
“Allergan Aesthetics’ global presence in the aesthetic space and goal to further enhance aesthetic medicine combined with Sirona’s disruptive technology made this all possible,” reports Dr. Linda Pullan, of Pullan Consulting.
Under the license agreement, Sirona will a receive an upfront payment and further payments on achievement of milestones and royalties on product sales and has also agreed to financial terms as a supplier of its compounds.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s current pipeline includes further cosmetic related products for cell preservation and repair, keloid therapy, scar therapy, anti-aging, anti-wrinkle, and cellulite treatment. In the pharmaceutical space, Sirona Biochem is working on a therapeutic for diabetic animals and new anti-viral therapies for humans. An extensive list of viable options for future programs applicable to the platform technology is maintained by Sirona’s chemistry team in France to ensure continued growth of the company.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s scientific development unit, TFChem in France, is recipient of multiple scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem CEO Quarterly Update
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to provide the following update to shareholders.
Dear shareholders,
We continue to make fundamental progress on core objectives and will be able to share more in due course.
TFC-1067
A comprehensive update is due in the near future. We can report there are no adverse events and proper disclosure rules are being followed. No further information will be made public at this point
TFC-039 / Animal Health
We are pleased to inform our shareholders that Sirona and Wanbang have signed a binding Letter of Intent (LOI) to collaborate on licencing efforts for Sirona’s SGLT2 inhibitor, TFC-039, as a treatment for diabetes in animal health. We have a long-standing relationship with Wanbang and are excited to combine our two companies’ expertise to license TFC-039 to a global animal healthcare company.
Previous efforts to license TFC-039 for this indication were delayed for reasons unrelated to the merit of the opportunity and interested parties are now able and willing to move forward. Discussions are rapidly progressing with several global companies to develop TFC-039 as a treatment for diabetes in companion animals. SGLT2 inhibitors provide an opportunity to treat inflicted animals with an oral medication as opposed to the traditional method of daily insulin injections.
The combined scientific knowledge of Sirona and Wanbang will significantly increase the speed to commercialization of TFC-039. This includes extensive data, advanced manufacturing process development and the ability to commercially manufacture TFC-039. The new agreement was a desired step on the part of the interested partners to create the legal framework and to have certainty regarding production capacities and costs. Now that this has been finalized , the probability of a successful licensing agreement in the near future has been made much stronger.
This LOI is a modification of a previous agreement signed February 8th, 2021 which was mentioned in the CEO Update of 24 February 2021. The agreement will focus solely on applying TFC-039 to animal health.
Studies on a new indication for TFC-039 are also ongoing. Details of the new indication cannot be disclosed, but the opportunity as a valuable therapeutic exists and is an area of great need.
Anti-Aging
The lead compound for anti-aging will enter small scale-up and formulation for use in clinical and stability studies. We anticipate the clinical trial to take place in the second half of 2022.
Furthermore, our IP keeps growing – see latest entry for TFChem in the WIPO database.
Antiviral
As announced on 20 December 2021, we have had 20 antiviral compounds tested by Utah State University’s Institute of Antiviral Research.
The tests proved to be inconclusive. A known antiviral that was used as a positive control failed to produce results suggesting the test was not performing for this class of compounds. We’re now working on how to evaluate the compounds with a new assay. Accordingly, we are in the process of identifying other options or providers for testing our compounds and are currently coordinating how to proceed.
We remain no less confident that our antiviral compounds will deliver convincing results.
Due to these results, our discussions with potential partners in both public and private sector are on hold.
Anti-Cellulite
Due to our work on licensing agreements, we have diverted resources from this project at this time and will resume focus on this and other innovative pipeline projects when we’ve closed our deals.
Events
We will be participating in person with partnering meetings during BIO International June 13-16 in San Diego. BIO One-On-One Partnering(TM) opportunities with over 15,000 biotechnology leaders the largest of its kind. For more information, please visit https://www.bio.org/events/bio-international-convention
Financials
In February 2022, 12,258,960 warrants were exercised for proceeds of $1,961,434.
In addition, as announced on March 9, 2022, our wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients.
Furthermore, and most importantly: we anticipate very significant positive corporate developments that will completely change the company’s financial situation – for the long term.
Dr. Howard Verrico, CEO
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem Subsidiary, TFChem, Awarded Financing in Partnership with French Government
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona“) is pleased to announce that its wholly owned subsidiary TFChem, has been awarded financing to develop an advanced chemistry process that could improve the manufacturing of active ingredients.
The project will be financed in partnership with the French government and will include the University of Rouen in Normandy, the Engineering school INSA of Rouen and the CNRS (The French National Centre for Scientific Research – among the world’s leading research institutions) to develop “flow chemistry”, an advanced technology for multistep syntheses of compounds.
Flow chemistry allows for a continuous flow manufacturing of organic molecules rather than batch type manufacturing. The technology provides several advantages to the process development of Sirona’s compounds and actives by reducing the cost of production, preventing the formation of secondary products and improving the security of certain chemical reactions.
The French government will co-finance and hire a postdoctoral student full time on the project and will allow the free use of a facility at the university as well as access to the specialized equipment required to develop the process. The student will share time between TFChem’s laboratory in Val de Reuil and the Institute of Organic chemistry in Rouen (IRCOF). The contract will be for one year.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Canada
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communications support.
The agreement has been signed for an additional year of services.
“We have been utilizing the powerful tools provided by CURE Intelligence which keep us informed on relevant market developments and opportunities that relate to our growing pipeline of projects. We have benefited greatly from the intelligence provided to our team members both for scientific and business development opportunities,” said Dr. Howard Verrico, CEO of Sirona Biochem. “We look forward to continuing our relationship with the team at CURE. They have proven their ability to add significant value and improve our communications and market intelligence. We continue to fine-tune these services as we utilize their full potential well beyond communication support.”
“In 2021, Sirona Biochem achieved a very significant milestone with the launch of a commercial product containing a Sirona compound. A great deal of progress was made in business development and scientific research which provides an excellent basis for further positive developments in 2022. We are very much looking forward to continuing to provide Sirona Biochem with relevant market information and contacts, and to raise awareness of the company and its products among investors, partners and the trade press,” comments Marco Feiten, Managing Director at CURE Intelligence.
About CURE Intelligence
Founded in 2009, CURE specializes in the field of media monitoring and analysis, data intelligence, social media communications and marketing. CURE helps its clients make better decisions and improve internal and external communication by effectively combining analytics and marketing.
CURE is a public limited company with its headquarters in Grevenmacher, Luxembourg and a subsidiary in Cologne, Germany. CURE works with internationally renowned clients from Germany, Luxembourg, Brazil, Canada and the U.S. For more information, please visit www.cure-intelligence.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
For more information regarding this press release, please contact:
Investor Enquiries:
Jonathan Williams
Managing Director
Momentum PR
Canada
Phone: 1.450.332.6939
Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem Antiviral Compounds to be Tested Against SARS-CoV-2 by Top US Testing Facility
Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) announces the advancement of 20 antiviral compounds to In Vitro testing. The compounds will be shipped to the Utah State University’s Institute of Antiviral Research for evaluation against the SARS-CoV-2 virus (COVID-19).
Sirona’s French subsidiary, TFChem, has created a novel and patentable library of 20 compounds that are designed to target the COVID-19 virus by targeting the host cell and not the virus itself. When a virus enters a cell, it induces a “cytopathic effect” which refers to structural changes in the host cell, that allow the virus to replicate. In SARS-CoV-2, the virus causes plaque-like effects in the human cells of the lung. Mechanisms such as cell fusion, apoptosis (death) and destruction of epithelium integrity are all observed in the plaque regions (Nature Communications, 2020, https://www.nature.com/articles/s41467-020-17796-z). Sirona’s antiviral compounds are intended to prevent the cytopathic effect from occurring.
The results will be completed in approximately 6 weeks.
“Since the compounds are designed to target the host cell and not the virus itself, we have a unique approach that is based on our proprietary technology. We have seen the number of variants that the SARS-CoV-2 virus has. It will continue to mutate, creating new strains, so there is a strong need for compounds like these that are not targeted to a specific virus,” said Dr. Howard Verrico, CEO of Sirona Biochem. “It is now time to push this program as quickly as possible, adding to a robust and valuable pipeline that will attract the right kind of partners. For this project, we have already been in preliminary discussion with a company that has expertise in antiviral clinical trials. The results from these preliminary studies will be key to moving forward with potential partners in 2022.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem
Sirona Biochem Announces Engagement of Pullan Consulting to Close Optimal Deal for TFC-1067
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is very pleased to announce that Linda Pullan of Pullan Consulting will be providing strategic direction with the negotiations and licensing of TFC-1067.
Sirona is in the negotiation phase with a global top 10 pharmaceutical company for the rights to TFC-1067. Simultaneously, the company is completing the legal due diligence regarding contracts and patents, which is a straightforward task. The pharma company is advancing on the project as expected and has been transparent with next steps and timelines.
“We are thrilled to have Pullan Consulting on board to assist us with this task. Linda has successfully closed 65 pharma/biotech deals and has advised on many more. She is a renowned professional in the field,” said Howard Verrico, CEO of Sirona Biochem. “We are dealing with a pharmaceutical company that is very experienced in licensing negotiations. The highest level of expertise is needed to obtain the best outcome. We see this level in Pullan Consulting and look forward to working with their team to close an optimal deal.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2021/16/c3558.html
Contact:
Investor Enquiries: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in News Home, Sirona Biochem
Sirona Biochem Provides Update on SGLT2 Inhibitor for Type 2 Diabetes in China
Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) announces that it has received notice that the development of Sirona’s SGLT2 inhibitor, TFC-039, will be discontinued by Wanbang Biopharmaceuticals (“Wanbang“) as a treatment for type 2 diabetes in China.
TFC-039 was licensed to Wanbang, a wholly owned subsidiary of Shanghai Fosun Pharmaceutical Group, in 2014. Sirona received a total of USD 1.5 million in up front and milestone payments.
“To this point, Wanbang has remained dedicated to the development of the drug, completing the IND and advancing through and completing its Phase I clinical trials. During 2021, they indicated that they were extensively analyzing the clinical results and that delays were the result of COVID closures and restrictions. This year, Empagliflozin (developed by Boehringer Ingelheim and Eli Lilly) failed to uphold patent protection in China, which created a generic environment for SGLT2 inhibitors. It was reported to us TFC-039 performed well in the clinical trials, however, given the generic situation, it did not make good business sense for Wanbang to continue a lengthy and costly development”, said Dr. Howard Verrico, CEO of Sirona Biochem.
“While this is disappointing, we still see a path forward for TFC-039. We are working on several opportunities (both existing and new) for animal care globally. Our science team is also working on a new therapeutic indication, with potential strong advantages for TFC-039 compared to other compounds of the same class. This new indication has both unmet need and tremendous commercial value. The work done to date by Sirona and Wanbang will provide added value towards these opportunities, and we will also explore future involvement with Wanbang. Further dialogue will be occurring between Wanbang, and Sirona and any material news will be released accordingly.”
About Wanbang Biopharmaceuticals and Fosun Pharmaceuticals
Wanbang Biopharmaceuticals develops, manufactures and sells drugs with indications for chronic disease treatment, antibiotics, and other endocrine diseases in China. Founded in 1981, they are presently headquartered in Xuzhou, China, and are a subsidiary of Shanghai Fosun Pharmaceutical Group. Fosun is a leader in the pharmaceutical industry and regarded as one of the top five domestic pharmaceutical companies in China. For more information on Fosun and Wanbang, please visit www.fosunpharma.com/en.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem
Sirona Biochem Announces 2021 Annual Meeting Results: Shareholders Approve All Resolutions With Majority Vote
Sirona Biochem Corp. (TSXV: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona“) is pleased to announce the voting results from its Annual General Meeting of Shareholders (the “Meeting”), held in Vancouver, British Columbia on November 10, 2021. The total number of shares represented by shareholders present in person and by proxy at the meeting was 33,335,079, representing 14.45% of Sirona’s issued and outstanding Common Shares.
All matters put forward to shareholders for consideration and approval, as set out in the Company’s Management Information Circular dated 12th of October, 2021, were approved by the requisite majority of votes cast at the Meeting. These were:
1. To elect Sirona’s board of directors; 2. to fix the number of directors of the Company at five; 3. to appoint DeVisser Gray LLP, Chartered Professional Accountants, as the Company’s auditor for the ensuing year and authorize the directors to set the auditor’s remuneration; and 4. to confirm and approve the Company’s existing stock option plan.
“We thank our shareholders for their participation and continued support,” said Dr. Howard Verrico, CEO of Sirona. “We look forward to further building and commercializing our pipeline.”
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
- Published in News Home, Sirona Biochem